The impact of GAS5 rs145204276 on development and prognosis of prostate cancer

The long non-coding RNA (lncRNA) GAS5 can be a marker for early diagnosis and postoperative follow-up in the patients with prostate cancer, whereby lower levels of GAS5 correlate with tumorigenesis and unfavourable clinical course. Expression of the GAS5 can be affected by rs145204276 polymorphism, a 5 base pairs insertion-deletion polymorphism shown as ?AGGCA/-?. The aim of this study was to analyse the association between rs145204276 and prostate cancer susceptibility and prognosis. This study was included 121 healthy subjects and 70 patients with prostate cancer. Diagnosis of prostate cancer was established by histopathology after the surgery. Genotyping was performed by allelic discrimination method using the TaqMan? assay. In the healthy subjects, the obtained frequencies of GAS5 rs145204276 genotypes were 80.2% of ins/ins, 16.5% of ins/del and 3.3% of del/del. The allele frequencies were 88.5% of ins and 11.5% of del, respectively. In the patient group, the frequencies of ins/ins, ins/del and del/del genotypes were 70%, 20% and 10%, respectively; the frequency of ins allele was 80% and the frequency of del allele was 20%. Observed frequencies of GAS5 rs145204276 genotypes were not significantly different between healthy subjects and patients with prostate cancer, and also between prognostic groups of prostate cancer. This study demonstrate no significant association between GAS5 rs145204276 and sussceptibility/prognosis of prostate cancer.